ERBB2 and breast carcinoma: For example, the EGFR tyrosine kinase inhibitor (TKI) gefitinib [6] has been extensively investigated and studies suggested that this drug can be effective against breast cancers expressing EGFR, especially in the background of HER2 overexpression [7-9].